Sanifit is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular calcification, particularly in patients with end-stage kidney disease. Operating in the biopharmaceutical sector, Sanifit serves patients suffering from severe cardiovascular conditions linked to chronic kidney disease. The company's primary product, SNF472, is designed to inhibit the progression of cardiovascular calcification, a major cause of morbidity and mortality in these patients. Sanifit generates revenue through funding from international investors, including venture capital funds, corporate venture funds, and private investors. The company has raised over 130 million euros in equity to date. Sanifit operates out of Palma de Mallorca, Spain, and San Diego, USA, and actively participates in investor conferences to secure additional funding and partnerships.

Keywords: cardiovascular calcification, end-stage kidney disease, biopharmaceutical, SNF472, clinical-stage, innovative treatments, chronic kidney disease, venture capital, international investors, morbidity and mortality.